Jim Cramer's Mad Money In-Depth Stock Picks, Oct. 3

Stocks discussed in the in-depth session of Jim Cramer’s Mad Money TV program, Tuesday October 3. Click on a stock ticker for more analysis:

New Pharma: Arena Pharmaceuticals (ARNA), ZymoGenetics (ZGEN), Myogen (MYOG), Gilead Sciences (GILD)

On his Jan 11th show Cramer was recommending ZGEN and MYOG as his two favorite pharma stocks, and since then ZGEN is down although he still likes it and MYOG has jumped 50% and is going to be taken over by GILD. Cramer believes that Arena will be the next MYOG since it has a weight loss drug in the pipeline which should be a "huge revenue generator" and the company may be an attractive acquisition.

Worst of the Best: DivX (DIVX), Akamai Technologies (AKAM), Arris (ARRS), Cisco (CSCO), Motorola (MOT), and Time Warner Cable (TWX)

Cramer suggests taking some DivX, a stock he recommended last week, off the table since it has moved up. His next pick is Arris which although it has been a "disappointment" and a "dicey stock" could be "the next Akmai" and is a triple play of cable, internet and telephone. Although MOT and CSCO could overwhelm Arris, Cramer observes "so far they haven't been able to nip at it, and they shouldn't be able to anytime soon," and that Arris has just signed a two year contract with TWX. Cramer says that ARRS demonstrates his point that even the worst of breed stock may be worth buying in a great sector.

Related: Bill Simpson takes an in-depth look at DivX's IPO.

High Rollers: Harrah's Entertainment (HET), MGM Mirage (MGM)

Cramer congratulates those who picked up HET before it received offers from private equity firms Apollo Management and Texas Pacific. For those who didn't join in the game the next big player could be MGM Mirage which Cramer believes is a better company than HET because MGM has Macau potential and because it has low downside risk. Although he is does not feel certain that MGM will get a bid Cramer feels that it is worth picking up.

Related: Chad Brand is skeptical about HET's buyout offer.

CEO Interview: Paul Sarvadi, Administaff (ASF)

Paul Sarvadi discussed the company's 32% earnings growth last quarter and its policy of buying back shares; "We look at our buyback program as a way to invest some of our cash," Sarvadi said. "Whenever the stock price is at a level that makes it such a tremendous value, we buy it back." He also mentioned that ASF's multiple is currently in the low 20s although it has historically been in the30s or higher.

More: Cramer's latest stock picks, including: Mad Money Recap, Lightening Round, Stop Trading and his Radio Show.

Get Cramer's Picks by email -- it's free and takes only a few seconds to sign up.

Seeking Alpha is not affiliated with CNBC, Jim Cramer or TheStreet.com.

Comment on this Article

Comments

[Ben Zelin]

Cramer did NOT say "(A)lthough MOT and CSCO could overwhelm DivX...." He was speaking about Arris (ARRS), not DivX. He had just explained that Arris is a competitor of MOT and CSCO. Obviously, DivX is not. This should be corrected with "Arris" substituted for "DivX" in Miriam Metzinger's summary.

[MiriamMetzinger]

Ben:
Thank you very much for the feedback. I have made the correction and apologize for the confusion.

Miriam Metzinger
Seeking Alpha